Real-time continuous in vivo drug monitoring

Dear All: 

I recently became aware of a technology for real-time continuous in vivo monitoring of drug levels that I thought worth sharing with the broader community. Although we’ve for many years had continuous measures of analytes such as glucose or oxygen where simple chemistry gave a suitable measurement tool, measurement of arbitrary analytes has not previously been something that could be readily achieved.

As described in a new PNAS paper by Arroyo-Currás et al., there is now a technology that addresses this challenge. The idea starts with noting that aptamers (oligonucleotides with high affinity for specific molecules) undergo a conformational change when they bind their target. This change can be detected electrochemically if the aptamer is bound to a suitable electrode. In addition, Jennifer Hoover (GSK) and Kevin Plaxco (originator of the technology) have written a white paper that you can review for additional details.

While we’ve managed to work for many years with blood level monitoring using the sample-and-test strategy, the idea of being able to get instant levels is fascinating and might simplify some aspects of drug R&D. Many thanks for Jenn & Kevin for bringing this to my attention. Kevin would be happy to be contacted at kwp@chem.ucsb.edu if you’d like to explore ways to collaborate with him.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://13.43.35.2/blog.html

Upcoming meetings of interest to the AMR community:

Share

Conflict-Borne XDR Superbugs: It’s Time for the PASTEUR Act!

Dear All: The recent publication of an exceptionally good plain-language summary of the AMR problem in Rolling Stone (yes, you read that correctly!) prompts today’s 3-part journey into the way(s) that war contributes to the threat of resistant superbugs. We’ve summarized the story in outline form — please explore the references for further details. And

ENABLE-2 funding now includes Hit Identification & Validation

23 July 2024 addenda x 2:  Mark Blaskovich let me know that the CO-ADD project is still offering a free in vitro screening service. See https://www.co-add.org/ to submit compounds for free testing vs 5 bacteria and 2 fungi; see https://db.co-add.org/ for structures and screening data on >100K compounds. The GHIT Fund has announced its 21st Request for Proposals for its Hit-to-Lead Platform to

NIAID/DMID thinking for FY2026: Antibacterials, Phage, and Antifungals

Dear All, NIAID’s DMID (Division of Microbiology and Infectious Diseases) recently held a council meeting during which they proposed program concepts that encompassed both antibacterial therapies (including phage) as well as antifungal therapies for funding in FY 2026 (the year that would run from 1 Oct 2025 to 30 Sep 2026). There is no guarantee that

WHO Antibacterial Pipeline Review: Update thru 31 Dec 2023

Dear All, WHO have released an update through 31 Dec 2023 of their ongoing series of antibacterial pipeline reviews! Here are the links you need: The report: 2023 Antibacterial agents in clinical and preclinical development: an overview and analysis and a press release about the report. Infographics: Key facts and recommendations from the 2023 antibacterial agents in clinical

Scroll to Top